| Ytd | -23.66% | |
| 1y | -41.85% |
| Open | 1.86 | Prev Close | 1.87 | Low | 1.85 | High | 1.90 | Mkt Cap | 107.15M |
| Vol | 29.39K | Avg Vol | 1.74M | EPS | -0.64 | P/E | -2.92 | Forward P/E | -1.80 |
| Beta | 3.25 | Short Ratio | 11.67 | Inst. Own | 98.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 2.13 | 200-d Avg | 2.73 | 1yr Est | 14.50 |
BDTX News
Black Diamond Therapeutics trades below cash value, offering a compelling risk/reward profile in pre
Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality w
BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profi
Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and do
Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving av
Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS act
CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX),
Black Diamond Therapeutics NASDAQ: BDTX reported updated Phase 2 data for silevertinib in treatment-
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX),
Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass.
Black Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and cont
Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including prelimin
Investors need to pay close attention to BDTX stock based on the movements in the options market lat
Black Diamond Therapeutics hinges on silevertinib, with 2026 data on progression-free survival and d
Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistanc
BDTX rides on silevertinib, with 2026 durability data set to test early NSCLC efficacy and CNS signa
CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX)
Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock?
BDTX spotlights silevertinib's 86% CNS response in NSCLC, with 2026 durability data and a glioblasto
BDTX hinges on silevertinib's mutation breadth and CNS activity, with 2026 data, cash runway, and pa
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pr
During Wednesday's trading, 517 companies set new 52-week lows.
On Tuesday, 838 companies hit new 52-week lows.
On Monday, 149 companies reached new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
Tuesday's session saw 211 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.